PDS Biotechnology (PDSB) Cash from Operations (2014 - 2025)
PDS Biotechnology's (PDSB) quarterly Cash from Operations came in at 3702585.0 in Q4 2025, up 55.04% YoY from 2388219.53 in Q4 2024, and up 37.41% on a QoQ basis from 5916048.0 in Q3 2025.
PDS Biotechnology (PDSB) Cash from Operations (2014 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Cash from Operations data on file, last reported at 3702585.0 in Q4 2025.
- Quarterly Cash from Operations rose 55.04% year-over-year to 3702585.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27752012.0 (up 20.78% YoY) and the FY2025 annual result came in at 27752012.0, up 20.78% from the prior year.
- Cash from Operations grew to 3702585.0 in Q4 2025, from 5916048.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 946225.0 in Q2 2021 to a low of 13188636.0 in Q1 2023.
- A 5-year average of 6730707.15 and a median of 6772469.5 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations soared 123.06% — and 2022, when it plunged 725.52%.
- Tracing PDSB's Cash from Operations over 5 years: stood at 4501395.0 in 2021, then sank by 67.26% to 7528933.0 in 2022, then declined by 12.33% to 8457176.0 in 2023, then rose by 2.63% to 8234439.0 in 2024, then soared by 55.04% to 3702585.0 in 2025.
- The last three Cash from Operations figures came in at 3702585.0 (Q4 2025), 5916048.0 (Q3 2025), and 9101123.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.70 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -5.92 Mn |
| Sep 30, 2025 | -5.92 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Dec 31, 2024 | -8.23 Mn |
| Dec 31, 2024 | -8.23 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Mar 31, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.94 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Sep 30, 2023 | -7.18 Mn |
| Sep 30, 2023 | -7.18 Mn |